Clinical Trials Browser

Phase 1 × Terminated × Albumin-Bound Paclitaxel × Clear all

NCT06199466 2025-12-08

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT03520790 2025-03-21

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT05911308 2025-03-21

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03435250 2024-07-25

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Phase 1 Terminated

Lymphoma

NCT04761601 2024-03-13

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumor

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 1 Terminated

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02514031 2022-06-03

ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT02608229 2021-04-21

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 1 Terminated

18 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Phase 1 Terminated

BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02267707 2019-11-01

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Phase 1 Terminated

Gastrointestinal

Cholestasis, Pancreatic Neoplasms

NCT00407407 2019-10-18

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Phase 1 Terminated

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02707328 2019-07-30

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Phase 1 Terminated

BreastGastrointestinalLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

NCT01090128 2017-03-31

NAC

Phase 1 Terminated

Stages II-III Breast Cancer

NCT01555853 2016-12-06

Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma

Phase 1 Terminated

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00337376 2014-01-14

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Phase 1 Terminated

Advanced Solid Cancers